H-NMR (500 MHz, CDCl 3 , δ / ppm): 10.30 (1H, s), 7.88 (1H, d, J = 2.5 Hz), 7.60 (1H, d, J = 8.5 Hz), 7.43 (1H, dd, J = 2.5 Hz, J = 8.0 Hz); CDCl 3 , δ / ppm): 190.49, 135.12, 135.03, 134.61, 134.44, 129.66, 124.61 2- . Colourless solid; m.p.: 76-78 °C; IR (ATR, cm -1 ): 3339, 3095, 3074, 3008, 2981, 2944, 2876, 2845, 2746, 1890, 1677, 1689, 1600, 1570, 1471, 1419, 1384, 1301, 1281, 1243, 1200, 1169, 1136, 1061, 1014, 932, 866, 820; 191.77, 159.25, 134.54, 133.95, 123.11, 117.95, 112.66, 55.71; GC-MS, RT 14.92 min (m/z (%)):
S222

3-[(Z)-2-(2-Bromo-5-chlorophenyl)ethenyl]-4-chloropyridine (24)
. Colourless powder; m.p.: 65-67 °C; IR (ATR, cm -1 ): 3107, 3081, 3054, 2967, 2928, 1754, 1732, 1639, 1572, 1546, 1471, 1449, 1404, 1386, 1309, 1267, 1224, 1204, 1166, 1109, 1087, 1023, 973, 936, 903, 882, 826; 150.92, 149.18, 143.29, 138.12, 133.99, 133.27, 132.17, 130.97, 130.12, 129.37, 126.03, 124.41, 121.77 
3-[(Z)-2-(2-Bromo-5-methoxyphenyl)ethenyl]-4-chloropyridine (25).
Colourless oil; IR (ATR, cm -1 ): 3397, 3007, 2935, 2835, 2356, 1618, 1591, 1567, 1464, 1411, 1346, 1295, 1237, 1174, 1129, 1082, 1052, 1016, 934, 872, 821; 59, 150.82, 148.40, 143.60, 136.99, 133.63, 133.58, 131.75, 124.84, 124.42, 115.70, 115.56, 114.33, 55.24 
3-[(Z)-2-(2-Bromo-5-fluorophenyl)ethenyl]-4-chloropyridine (26).
Colourless powder; m.p.: 109-110 °C; IR (ATR, cm -1 ): 3403, 3041, 2924, 2850, 1632, 1599, 1574, 1550, 1460, 1413, 1344, 1275, 1221, 1177, 1143, 1102, 1082, 1032, 962, 882, 819 ; 1 H-NMR (500 MHz, CDCl 3 , δ / ppm): 8.33 (1H, d, J = 5.5 Hz), 8.16 (1H, s), 7.54 (1H, dd, J = 5.5 Hz, J = 8.5 Hz), 7.34 (1H, d, J = 5.5 Hz), 6.90-6.75 (3H, m), 6.64 (1H, dd, J = 3.0 Hz, J = 9.0 Hz); 13 C-NMR (125 MHz, CDCl 3 , δ / ppm): 161.53 (d, J = 245.5 Hz), 150.98, 149.17, 143.29, 138.22 (d, J = 8.1 Hz), 134.18 (d, J = 8.1Hz), 132.46, 131.04, 125.93, 124.41, 118.20, 117.26 (d, J = 23.5), 116.67 (d, J = 22.6 Hz) ; (+)ESI-HRMS m/z: calcd. for propyl]-5H-pyrido [4,3-b] [1]benzazepine (27) . Yellow oil; IR (ATR, cm -1 ): 3340, 3023, 2960, 2874, 2792, 1635, 1577, 1480, 1418, 1393, 1329, 1241, 1184, 1142, 1125, 1058, 912, 830 79, 150.45, 150.08, 149.09, 134.12, 133.59, 129.47, 129.30, 129.19,129.06, 124.04, 121.08, 114.68, 54.23, 53.89, 48.50, 26.71, 23.37 ; (+)ESI-HRMS m/z: calcd. for [M+H + ]: 306.19647. Found: 306.19553. 5-[3-(Pyrrolidin-1-yl) propyl]-5H-dipyrido [4,3-b:3',4'-f]azepine (28) . Yellow oil; IR (ATR, cm -1 ): 3330, 3028, 2958, 2858, 2803, 1732, 1645, 1580, 1483, 1398, 1335, 1248, 1178, 1063, 929, 831 307.19172. Found: 307.19048. 3-(8-Chloro-5H-pyrido[4,3-b] -amine (29) . Yellow oil; IR (ATR, cm -1 ): 3387, 3026, 2944, 2858, 2817, 2768, 1682, 1578, 1472, 1391, 1327, 1241, 1184, 1132, 1101, 1058, 920, 841; 60, 150.62, 150.42, 147.46, 135.26, 132.73, 130.50, 129.34, 128.98, 128.96, 128.66, 122.27, 114.72, 56.89, 48.29, 45.45, 25.23 
3-(8-Methoxy-5H-pyrido[4,3-b][1]benzazepin-5-yl)-N,N-dimethylpropan-1--amine (30).
Yellow oil; IR (ATR, cm -1 ): 3381, 2944, 2858, 2819, 2768, 1674, 1634, 1578, 1480, 1394, 1322, 1276, 1244, 1206, 1038, 972, 938, 876; 36, 156.12, 150.53, 150.05, 141.73, 134.76, 133.68, 129.72, 128.82, 121.96, 114.69, 114.37, 114.08, 57.07, 55.47, 48.32, 45.50, 25.40 Pyrido[3', 4':6, 7] thiepino [3,2-c] 3965, 3356, 3080, 3048, 3021, 2959, 2928, 2855, 2024, 1989, 1952, 1919, 1894, 1852, 1812, 1754, 1676, 1630, 1569, 1546, 1468, 1395, 1362, 1306, 1273, 1195, 1163, 1099, 1053, 1027, 976, 946; 150.03, 144.42, 141.10, 135.08, 134.91, 134.75, 134.06, 131.67, 131.06, 129.68, 129.34, 126.27 3597, 3392, 3022, 2928, 2841, 1710, 1591, 1564, 1471, 1389, 1324, 1278, 1243, 1210, 1176, 1153, 1068, 1030, 926, 857, 829 3012, 2922, 2844, 2784, 2384, 1735, 1636, 1575, 1546, 1461, 1375, 1290, 1263, 1188, 1150, 1128, 1097, 1065, 813 04, 135.71, 133.88, 133.42, 133.36, 133.33, 132.48, 129.68, 129.16, 128.24, 58.28, 52.12, 45.15, 34.51 3389, 3026, 2925, 2852, 1670, 1565, 1542, 1470, 1389 ,1265, 1174, 1069, 1045, 836; 00, 149.90, 144.72, 141.95, 140.00, 139.71, 136.09, 135.40, 133.38, 131.59, 130.71, 128.90, 128.52, 128.41, 127.87, 127.04, 126.27 
HPLC ANALYSES FOR PURITY
Compounds were analyzed for purity (HPLC) using a Agilent 1200 HPLC system equipped with Quat pump (G1311B), injector (G1329B) 1260 ALS, TCC 1260 ( G1316A) and detector 1260 DAD VL + (G1315C). All compounds were >95 % pure. The HPLC analyses were performed in diverse systems:
Method A
Zorbax Eclipse Plus C18 4.6×150 mm, 1.8 µ, S.N. USWKY01594 was used as the stationary phase. The eluent was made from the following solvents: 0.2 % formic acid in water (A) and methanol (B). The analysis were performed at the UV max of the compounds (at 250 nm, 254 nm or 270 nm) to maximize selectivity. The compounds were dissolved in methanol; the final concentrations were ≈1 mg ml -1 . The flow rate was 0.5 ml min -1 .
Compounds 8-15, 27, 29, 30 and 34 were eluted using the gradient protocol: 0 -1 min 95 % A, 1 -5 min 95 % A → 5 % A, 5 -14 min 5 % A, 14 -15 min 5% A → 95 % A, 15 -16 min 95 % A.
Compounds 16, 17, 31, 32 and 33 were eluted using the gradient protocol: 0 -1.5 min 95 % A, 1.5 -5 min 95 % A → 5 % A, 5 -16 min 5 % A, 16 -18 min 5 % A → 95 % A.
Compound 35 was eluted using gradient protocol: 0 -1.5 min 50 % A, 1.5 -3 min 50 % A → 30 % A, 3 -6 min 30 % A → 0 % A, 6 -9 min 0 % A → 50 % A, 9 -12 min 50 % A.
Method B
Zorbax Eclipse Plus C18 4.6×150 mm, 1.8 µ, S.N. USWKY01594 was used as the stationary phase. The eluent was made from the following solvents: 0.2 % formic acid in water (A) and acetonitrile (B). The analyses were performed at the UV max of the compounds
